Atezolizumab news

Tecentriq reduces death risk by 41% and recurrence by 36% in bladder cancer using ctDNA guidance, sparing low-risk patients from unnecessary treatment.

Roche presents over 30 abstracts on cancer treatments, including breast, lung, and bladder cancers, at ESMO 2025, showcasing significant advancements in progression-free and overall survival.